Virus Testing in Frozen Berries: Sampling, Controls and Interpreting the Report

A frozen-berry virus report needs to be read with its sample identity, method scope and analytical controls. A target reported as not detected is useful only within the conditions under which the laboratory could detect it. An inhibited reaction, inadequate process recovery or missing control can leave the question unresolved. We therefore agree the berry lot and testing purpose before commissioning work, and preserve the original report when further analysis is needed.

For importers and food manufacturers, the purchasing decision concerns a defined quantity of product and its intended use. The laboratory result concerns the material actually submitted and analysed. Connecting those two scales requires a sampling plan, custody records, a competent laboratory and an authorised disposition. The DEMO records below explain that connection. They are invented examples, without a GreenLand shipment, customer, laboratory result or legally prescribed sampling plan behind them.

The commissioning question may be routine supplier verification, a destination requirement, investigation of a complaint or follow-up to a particular finding. Those purposes should not be merged in a generic request for a clean certificate. An investigation may require comparison between retained and arrival material, whereas routine verification needs a repeatable sampling programme. Specify whether the requested target is hepatitis A virus, norovirus genogroup I, norovirus genogroup II or another expressly named target. A bacterial COA does not answer those virological questions.

Historical surveillance helps explain why berry buyers ask about viruses, but its population results do not predict an individual order. The FDA's frozen-berries assignment report describes sampling carried out from 2018 to 2023 and published in 2025. It is evidence about that assignment. It is not a prescribed GreenLand sample count, proof of one origin's current performance or a substitute for a particular lot file. Keep surveillance context separate from the acceptance criterion used for the purchase.

Before samples leave the factory, the quality contact and buyer should approve one short commissioning record: product and lot boundary, testing purpose, target viruses, proposed method, sample collection and transport, required report details, and who decides the stock status. If those inputs are unresolved, a quick test can produce an expensive answer to the wrong question. Sales can coordinate the enquiry, while the laboratory confirms analytical capability and the designated quality authority retains the release decision.

Select an appropriate method and accredited scope

Ask the laboratory to identify the method and version it will actually use. The public scope of ISO 15216-1:2017 describes quantification of hepatitis A virus and norovirus GI and GII RNA in specified matrices, including soft fruit. That public description is not the full purchased standard. Part numbers and amendments matter, and a report based on qualitative detection should not be described as a quantitative concentration measurement simply because both methods use real-time RT-PCR.

Laboratory accreditation should be checked at the level of the requested matrix, target and method. A certificate naming food microbiology can be broader than the scope of an accredited berry-virus service. Read the current scope or ask the laboratory to identify the relevant entry, flexible-scope arrangements if applicable, and any subcontracted work. The original and subcontracting laboratories should remain identifiable in the evidence package. A logo on a commercial quotation cannot settle whether this particular activity is covered.

Product complexity is another boundary. A plain raspberry sample and a raspberry preparation containing dairy ingredients, starch, sweetener or other fruit are different analytical matrices. The laboratory may have suitable verification for additional materials, but the supplier should obtain that explanation before using a standard's name to imply automatic coverage. State the ingredients and processing history accurately. If a mixed-berry programme requires separate ingredient investigations, maintain those sample identities instead of treating the blend result as a direct measurement of each component.

An original accreditation case study published in 2023 explains the work involved in validating food-virus testing. It also states that the laboratory described had subsequently relinquished the relevant accreditation. The publication is therefore useful methodological background, not evidence that the named organisation currently offers an accredited service. This is a practical reason to check the live scope for every supplier approval and significant change, even when an older technical paper appears persuasive.

The enquiry should also settle report language and timing. Ask how the laboratory distinguishes a valid non-detection from an invalid analysis, how it identifies any dilution or additional purification, and what supporting explanation can be supplied when a control fails. Obtain an expected reporting pathway that includes sample receipt, preparation, review and possible investigation. A sales promise based only on instrument run time can overlook the work needed to produce an interpretable authorised report.

Collect representative units and preserve frozen sample identity

Sampling is a physical operation with consequences that cannot be repaired by a detailed PDF. Identify who selects the cartons, which lot locations can be reached, whether units are selected at production or from stored pallets, and how the selection is recorded. A sample taken from the easiest carton near the cold-store door may answer a different question from a planned selection across the declared lot. Record any inaccessible stock and explain the resulting limitation before claiming representative coverage.

For a labelled DEMO, imagine a lot stored in three identifiable zones, A, B and C. Two sealed cartons are selected from each zone and receive sample identities A1, A2, B1, B2, C1 and C2. This six-carton arrangement is an illustration of traceability, not a recommended universal sample count. The real number of increments, analytical units and test portions depends on the applicable programme, contamination question, laboratory method and acceptance rule. Keep those three quantities in separate fields because they need not be equal.

If material is combined, the laboratory must confirm that the proposed compositing is suitable for the method and purpose. Pooling changes the material entering analysis and may affect sensitivity or the ability to locate a finding. It must not be used merely to produce a lower invoice while the report still appears to contain independent results for the original units. Retain the relationship between the collected cartons, any composite and the actual analysed portions. The sampler's account should make that relationship understandable without reconstructing it from email.

Sample custody includes the container, seal where used, amount submitted, product condition, collection time and person, dispatch event and laboratory receipt. Maintain the condition required by the agreed sampling and laboratory procedure, and record deviations rather than concealing them. A missing label, thawed arrival or broken sample closure should be referred to the laboratory and quality owner before the material is accepted for its intended decision. A result can be analytically precise while its sample identity remains inadequate.

Preserve retained portions only under a defined procedure. State whether they are a split of the submitted material, another carton from the same production lot or a sample from another packing date. Those are useful but different resources. Include retention location, custody and storage records, permitted uses and the person authorised to request further testing. A second analysis of an old extract and a new sample collected from the lot should never appear in the file as interchangeable repetitions.

Read process recovery and inhibition controls with the result

Real-time RT-PCR detects selected viral RNA sequences after extraction and amplification. The report needs sufficient information to establish that the analytical pathway was interpretable for the submitted material. Different controls address different parts of that pathway. A process control can help assess recovery through the preparation, while amplification-related controls help identify inhibition or failures at a later stage. Negative and positive controls also have defined roles. Ask the laboratory to explain its actual control scheme rather than assuming that one green check covers every stage.

Berries can be a demanding matrix. An original frozen-strawberry method comparison found differences associated with RT-PCR inhibitors and sample preparation. A 2024 extraction-platform study also reported matrix-dependent performance in artificially contaminated produce. These studies support asking about performance in the actual material. Their experiments do not set a universal commercial recovery threshold, and their numeric findings should not be copied as routine acceptance limits for every berry programme.

The laboratory should apply the control criteria belonging to its validated method and report convention. If a control fails, ask which result is affected and what action the method permits. Depending on the investigated cause, the laboratory may examine the extract, apply an authorised additional treatment, repeat extraction or request another portion. The supplier should not prescribe an improvised laboratory adjustment merely to obtain a convenient non-detection. Record the laboratory's interpretation and keep the original observation visible.

Dilution needs careful explanation. It can change the effect of an inhibitory matrix, but it also changes the amount of original material represented by a reaction and may affect the reporting capability. An improvement in control performance is therefore not automatically an unchanged detection limit for the product. Ask the laboratory how it reports the final result and associated capability after dilution. The customer should receive a meaningful product-basis interpretation, not just a favourable-looking curve from a different preparation.

In the DEMO six-unit file, suppose A1 and A2 are reported as valid non-detections, B1 has an invalid analysis because a required control did not meet its criterion, B2 has target RNA detected, and C1 and C2 remain pending. There are two valid non-detections, one invalid analysis, one detection and two pending results. Reporting this as five negatives and one positive would erase three unresolved outcomes. The stock decision must use the applicable rule and authorised investigation, with each sample's status preserved separately.

On narrow screens, scroll the figure to read every label.

Schematic amplification traces illustrate differing control behaviour; no Ct cutoff or measured assay result is supplied.

The internal review can make the six statuses auditable without inventing additional laboratory data. Enter one row for each of the six sample codes, copy the laboratory wording into an original-result column, and place the reviewer action in a separate column. A1 and A2 can read valid non-detection; B1 needs laboratory investigation; B2 needs target-finding escalation; C1 and C2 remain pending. A supervisor can then reconcile six collected units with six known statuses. The action column must not overwrite the original-result column when a supplementary report arrives.

Assign documents the same way. The sampling sheet supports where A1 came from; the laboratory receipt supports what material arrived; the report supports what the laboratory concluded; the disposition record supports the stock decision. If one attachment is missing, the index should show that specific gap. A signed shipment summary does not create the absent sampling evidence. This simple document-to-question comparison also helps the customer request useful clarification: ask for the control interpretation behind B1, rather than asking sales to replace the report with a clean certificate.

Distinguish detected RNA, non-detection and invalid analysis

A report of target RNA detected establishes the analytical finding within the method's scope. It is not a direct measurement of infectivity. The converse also matters: the absence of a direct infectivity measurement does not make an RNA detection commercially or regulatorily irrelevant. The quality team must apply the applicable requirement, investigation and authority instructions. Neither the supplier nor the customer should dismiss a result by changing the question after seeing the outcome.

A valid non-detection has a defined target, matrix, analysed quantity and method capability. It supports the statement the laboratory actually issued for the analysed material. It does not prove the entire shipment contains no virus or that every upstream control performed correctly. Keep the wording narrow when transferring it to a supplier COA or customer summary. Quoting a laboratory's non-detection without its analysed amount or qualifier can make a limited observation appear to be a broader guarantee.

An invalid analysis is a separate status. It should remain visibly unresolved until the laboratory has completed and authorised the relevant follow-up. The supplier should not transcribe it into the same cell format used for not detected. A report with a missing control description may require clarification rather than being declared invalid by the buyer, since laboratories differ in how they present supporting information. Obtain the explanation and distinguish an actual method failure from an incomplete commercial summary.

Where a report includes genome-copy estimates, ask about the reporting basis and quantitative range. Copies per reaction, per extracted volume, per test portion and per gram of product are different quantities. Converting between them needs the method's actual volumes, masses and recovery or reporting convention where relevant. An import team should not invent the factors from a screenshot. Preserve the original result and ask the laboratory to provide the appropriate product-basis statement if that is needed by the order.

When several targets are requested, retain each target's result. Norovirus GI and GII should not disappear into an unexplained single virus column, and a hepatitis A result does not cover an untested target. The report review table can have separate columns for target, method, matrix, portion identity, result, qualifier, control interpretation, limitation and reviewer action. This is a comparison of actual analytical records, not an invitation to rank laboratories by the lowest-looking number.

Use retesting and tracing to answer the remaining uncertainty

Start an investigation by defining the unresolved question. Re-extracting a retained portion can help examine a preparation problem. Analysing another retained carton can provide information about another unit. Drawing a new lot sample may improve knowledge of a distribution problem. None automatically invalidates the original report. The investigation plan should state which material is used, why, what method applies and how all results will be assessed. Agree the plan before the next result is known.

Keep stock status explicit while the evidence develops. Record the affected production codes, cartons and locations, any shipment already dispatched, and the named quality owner. Physical identification and inventory status should agree. If another lot shares a source, line or packing period, investigate the connection instead of automatically declaring either full independence or universal involvement. The required scope is an evidence question. Explain what is known, what is being traced and which quantities remain under review.

In the six-unit DEMO, the invalid B1 analysis first requires laboratory clarification and an authorised analytical follow-up. The B2 detection raises a separate target-result investigation. Repeating B1 does not resolve B2, and an additional valid non-detection from C1 does not erase B2. A useful action log keeps those questions in different rows. It records who requested the action, the sample used, the original and supplementary report identifiers, and whether the action has changed the evidence or merely added information.

If a shipment is detained or an authority has issued instructions, the importer should coordinate the official response and keep the notice, affected identifiers and deadlines in the order file. GreenLand can organise product, source, sampling and laboratory documents that are actually available. A supplier website cannot promise that a private retest will secure release, or substitute a supplier decision for an authority's disposition. Keep private contract remedies, regulatory decisions and food-safety actions identifiable in the communication.

Trace corrective action beyond the report. Depending on the finding, the relevant enquiry may concern source water, personnel hygiene, field or harvest practices, processing handling, supplier verification or a sample-custody failure. Assign the work to the party with the actual information and authority. Close an investigation only when its question, evidence, product disposition and follow-up ownership are recorded. A revised certificate with the original adverse or invalid observation omitted is not a satisfactory investigation record.

The disposition record should identify the stock quantity, decision owner and open conditions. Possible actions include maintaining a hold, obtaining laboratory clarification, arranging an authorised additional sample, following official detention instructions or completing a documented release under the applicable requirements. These are conditional actions, not a universal sequence in which enough negative tests eventually produce approval. The order-specific quality authority needs the complete evidence and an explicit decision rule.

We can use the internal record to prepare a concise buyer handover: which product and lot were reviewed, which samples and targets were tested, the laboratory's authorised result wording, any remaining limitation and the current shipment status. Attach the original reports rather than replacing them with a sales summary. Do not claim an independent laboratory result unless an actual report exists for that sample. The worked file in this article remains a method demonstration until populated with genuine order records.

Review the programme when the source, factory, berry form, formulation, intended use, destination requirement or laboratory method changes. A repeat purchase is not necessarily an unchanged analytical question. Compare the new inputs with the approved file, assign the necessary review and preserve both versions. That gives purchasing a clear explanation of what GreenLand can prepare, what the laboratory must confirm and what the importer or qualified quality authority must decide before the order proceeds.